Table 1—

Demographic characteristics at baseline in the placebo/epoprostenol and bosentan/epoprostenol groups (intent-to-treat population)

CharacteristicPlacebo/epoprostenolBosentan/epoprostenol
Subjects n1122
M:F5 (45):6 (55)5 (23):17 (77)
Age yrs47±19 (15–68)45±17 (16–69)
Weight kg78±16 (53–103)70±21 (40–109)
Ethnic group
 Caucasian/White10 (91)18 (82)
 Black1 (9)1 (5)
 Asian1 (5)
 Other2 (9)
Aetiology of PAH
 Primary10 (91)17 (77)
 Scleroderma1 (9)4(18)
 Systemic lupus erythematosus1 (5)
Modified NYHA functional class
 III8 (73)17 (77)
 IV3 (27)5 (23)
Clinical signs of heart failure4 (36)10 (45)
Concomitant PAH medications (only when >4 in at least one group)
 Antithrombotic agents10 (91)19 (86)
 High-ceiling diuretics10 (91)19 (86)
 Potassium sparing agents5 (45)14 (64)
 Cardiac glycosides2 (18)7 (32)
 Calcium channel blockers3 (27)6 (27)
 Use of supplemental oxygen4 (36)6 (27)
Time since diagnosis months15±21 (1–61)13±30 (1–138)
  • Data are presented as n (%) of patients or mean±sd (range)

  • M: male

  • F: female

  • PAH: pulmonary arterial hypertension

  • NYHA: New York Heart Association